<DOC>
	<DOCNO>NCT00989690</DOCNO>
	<brief_summary>RATIONALE : Studying protein express sample blood tissue patient cancer may help doctor identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This randomized phase III trial study blood tissue sample predict response second-line therapy use erlotinib hydrochloride chemotherapy patient advance non-small cell lung cancer .</brief_summary>
	<brief_title>Study Blood Tissue Samples Predicting Response Second-Line Therapy Using Erlotinib Hydrochloride Chemotherapy Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To evaluate predictive value proteomic profile effect second-line therapy erlotinib hydrochloride v standard chemotherapy ( pemetrexed disodium docetaxel ) patient advance non-small cell lung cancer . - To assess role know tissue-based predictive marker ( e.g. , EGFR-gene copy number , EGFR-protein expression , pAkt , pMAPK , EGFR mutation , EMT marker , k-Ras mutation ) . OUTLINE : This multicenter study . Patients stratify accord smoking status , performance status , proteomic profile , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive standard chemotherapy pemetrexed disodium , docetaxel , another standard drug . - Arm II : Patients receive standard non-chemotherapy treatment erlotinib hydrochloride . Serum collect failure first-line therapy proteomic analysis matrix-associated laser desorption/ionization-time flight . Tissue blood sample collect periodically analysis include EGFR base IHC FISH , EGFR k-Ras mutation , pAkt , pMAPK IHC , EMT marker base IHC breath condensate protein profile . After completion study treatment , patient follow every 2 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm diagnosis nonsmall cell lung cancer ( NSCLC ) Advanced NSCLC ( stage IIIB IV ) Measurable disease Underwent previous treatment 1 nontyrosine kinase inhibitor firstline therapy advance NSCLC No clinical evidence uncontrolled brain metastasis PATIENT CHARACTERISTICS : Caucasian ECOG performance status 02 Absolute granulocyte count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( ≤ 2.5 time ULN patient know liver metastasis ) ALT AST ≤ 3 time ULN ( ≤ 5 time ULN patient know liver metastasis ) Creatinine clearance ≥ 50 mL/min Not pregnant nursing Able comply plan study procedure No multiple severe disease compromise safety ( cardiac renal failure , peripheral neuropathy ) No malignancy ( except basal cell skin carcinoma ) preneoplastic condition require chemotherapeutic treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 3 week since prior surgery radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>